Phase II study on first-line treatment of NIVolumab in combination with folfoxiri/bevacizumab in patients with Advanced COloRectal cancer RAS or BRAF mutated - NIVACOR trial (GOIRC-03-2018).

Angela DamatoFrancesco IachettaLorenzo AntonuzzoGuglielmo NastiFrancesca BergamoRoberto BordonaroEvaristo MaielloAlberto ZaniboniGiuseppe ToniniAlessandra RomagnaniAnnalisa BerselliNicola NormannoCarmine Pinto

Published in: BMC cancer (2020)

NIVACOR is registered at ClinicalTrials.gov: NCT04072198 , August 28, 2019.

Keyphrases

phase ii study
metastatic colorectal cancer
wild type
open label
phase iii
phase ii
locally advanced
study protocol
clinical trial
placebo controlled
squamous cell carcinoma
rectal cancer
double blind
radiation therapy